Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q68CP4

UPID:
HGNAT_HUMAN

ALTERNATIVE NAMES:
Transmembrane protein 76

ALTERNATIVE UPACC:
Q68CP4; B4E2V0

BACKGROUND:
The enzyme Heparan-alpha-glucosaminide N-acetyltransferase, known alternatively as Transmembrane protein 76, is integral to the lysosomal processing of heparan sulfate. By acetylating heparan sulfate, it converts it into a form that is readily degraded, thus preventing harmful buildup within lysosomes.

THERAPEUTIC SIGNIFICANCE:
Dysregulation of this enzyme's activity is implicated in diseases such as Mucopolysaccharidosis 3C, characterized by CNS degeneration, and Retinitis pigmentosa 73, leading to progressive vision loss. Targeting Heparan-alpha-glucosaminide N-acetyltransferase offers a promising avenue for developing treatments for these diseases, underscoring its therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.